文献速递类风湿关节炎

类风湿关节炎患者达到缓解后停用托珠单抗:单用或联合甲氨蝶呤治疗的前瞻性随机对照研究(SURPRISE研究第二年结果)

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
PubMed 文献 · Ann Rheum Dis · 2018-05-31

SURPRISE研究第二年纳入105例第52周达到缓解(DAS28-ESR<2.6)并停用托珠单抗的类风湿关节炎患者,ADD-ON组51例继续甲氨蝶呤,SWITCH组54例未用改善病情抗风湿药。ADD-ON组持续DAS28低疾病活动度率显著高于SWITCH组(55% vs 27%,p=0.005),持续缓解率两组无显著差异(24% vs 14%,p=0.29),影像学进展相当(mTSS 0.37 vs 0.64,p=0.36)。重启托珠单抗后除2例外均诱导缓解。

要点

  • 停用托珠单抗后继续甲氨蝶呤者持续低疾病活动度率55%,显著高于未用改善病情抗风湿药者的27%。
  • 第104周持续缓解率ADD-ON组24% vs SWITCH组14%,差异无统计学显著(p=0.29)。
  • 两组影像学进展相当(mTSS 0.37 vs 0.64,p=0.36)。

核心结论

  • 停用托珠单抗后继续甲氨蝶呤可使超过半数患者维持持续低疾病活动度。
  • 重启托珠单抗可使超过90%的患者达到缓解。

研究设计与样本

  • SURPRISE研究为2年开放标签随机对照研究,第一年随机分为加用托珠单抗组(ADD-ON)或换用托珠单抗组(SWITCH)。
  • 第一年达到缓解(DAS28-ESR<2.6)者在第52周停用托珠单抗并观察52周,共105例,ADD-ON组51例继续甲氨蝶呤,SWITCH组54例未用改善病情抗风湿药。

主要发现

  • 持续DAS28低疾病活动度率ADD-ON组55% vs SWITCH组27%,ADD-ON组显著更高(p=0.005)。
  • 第104周持续缓解率ADD-ON组24% vs SWITCH组14%(p=0.29)。
  • 影像学进展两组相当(mTSS 0.37 vs 0.64,p=0.36)。
  • 重启托珠单抗后36周内除2例外均诱导缓解,与是否联用甲氨蝶呤无关。

关键数值与推荐

  • 缓解定义为DAS28-ESR<2.6。
  • 持续DAS28低疾病活动度率ADD-ON组55% vs SWITCH组27%(p=0.005)。
  • 第104周持续缓解率ADD-ON组24% vs SWITCH组14%(p=0.29)。
  • mTSS ADD-ON组0.37 vs SWITCH组0.64(p=0.36)。

临床怎么用

  • 停用托珠单抗后继续甲氨蝶呤可使超过半数患者维持持续低疾病活动度。
  • 重启托珠单抗可使超过90%的患者达到缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the sustained remission and low disease activity after discontinuation of tocilizumab in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate. METHODS: The SURPRISE study was a 2-year, open-label randomised controlled study. Among patients who had been randomised to additional tocilizumab (ADD-ON) or switch to tocilizumab (SWITCH) in the first year, those who achieved remission based on the disease activity score for 28 joints (DAS28-ESR<2.6) discontinued tocilizumab at week 52 and were observed for the following 52 weeks. The endpoint of the second year included tocilizumab-free remission and low disease-activity rates, functional outcome, radiological outcomes assessed with the modified total Sharp score (mTSS) and safety. The efficacy of reinstituted tocilizumab/methotrexate was also evaluated. RESULTS: A total of 105 patients who achieved remission at week 52 discontinued tocilizumab; 51 in ADD-ON continued methotrexate and 54 in SWITCH received no disease-modifying antirheumatic drugs. Sustained DAS28 low disease-activity rates were significantly higher in ADD-ON than in SWITCH (55%vs27%, p=0.005). Sustained remission rates at week 104 were 24% for ADD-ON and 14% for SWITCH (p=0.29). Radiological progression was comparable between both groups (mTSS; 0.37vs0.64, p=0.36). The restart of tocilizumab induced remission in all except two patients after 36 weeks, irrespective of concomitant methotrexate. CONCLUSION: Sustained low disease activity after tocilizumab discontinuation could be maintained with continued methotrexate in more than half of the patients. Retreatment with tocilizumab led to remission in more than 90% of patients. TRIAL REGISTRATION NUMBER: NCT01120366; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kaneko Y, Kato M, Tanaka Y, et al. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Ann Rheum Dis. 2018. PMID: 29853455. doi:10.1136/annrheumdis-2018-213416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。